Oruka Therapeutics, Inc.
ORKA
$67.90
$0.971.44%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 42.20% | 87.93% | -- | -- | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 25.44% | 38.50% | -- | -- | -- |
| Operating Income | -25.44% | -38.50% | -- | -- | -- |
| Income Before Tax | -19.06% | -37.56% | -- | -- | -- |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -19.06% | -37.56% | -- | -- | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -19.06% | -25.93% | -- | -- | -- |
| EBIT | -25.44% | -38.50% | -- | -- | -- |
| EBITDA | -57.15% | -104.15% | -- | -- | -- |
| EPS Basic | 79.23% | 92.32% | -- | -- | -- |
| Normalized Basic EPS | 76.11% | 75.61% | -- | -- | -- |
| EPS Diluted | 79.23% | 92.32% | -- | -- | -- |
| Normalized Diluted EPS | 76.11% | 75.61% | -- | -- | -- |
| Average Basic Shares Outstanding | 95.71% | 212.38% | -- | -- | -- |
| Average Diluted Shares Outstanding | 95.71% | 209.91% | -- | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |